The results of the<unk> -TIMI<unk><unk>  were recently presented in AHA November 2011 held at Orlando, Florida. The multicentric randomized double blinded<unk>  was able to show that increasing the maintenance doses of<unk>  to 225 mg daily in CYP2C19 heterozygotes patients with stable cardiovascular diseases, were able to cause similar levels of platelet reactivity as seen with the standard 75-mg dose in non-carriers. However, in patients who were homozygotes for CYP2C19 genes, doses as high as 300 mg daily did not result in comparable degrees of platelet inhibition.
Clopidogrel dosing and role of genetics: ELEVATE-TIMI 56 trial
Chronic stable angina COURAGE trial
PCI: classification of the lesion
Antihypertensive and lipid-lowering treatment to prevent heart attack trial
Unstable angina / non ST elevation myocardial infarction GPIIb/IIIa inhibitor
Chronic stable angina PCI and CABG versus medical therapy
TIMI Risk Score for Unstable Angina or NSTEMI
Chronic stable angina ACC/AHA guidelines for alternative therapies in patients with refractory angina